MX355467B - Therapeutic antibodies. - Google Patents

Therapeutic antibodies.

Info

Publication number
MX355467B
MX355467B MX2013013911A MX2013013911A MX355467B MX 355467 B MX355467 B MX 355467B MX 2013013911 A MX2013013911 A MX 2013013911A MX 2013013911 A MX2013013911 A MX 2013013911A MX 355467 B MX355467 B MX 355467B
Authority
MX
Mexico
Prior art keywords
antibodies
human
receptor
c5ar
therapeutic antibodies
Prior art date
Application number
MX2013013911A
Other languages
Spanish (es)
Other versions
MX2013013911A (en
Inventor
Zahn Stefan
Hjerrild Zeuthen Louise
Jon Hansen Anker
Kjaergaard Kristian
Lund Søren
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Priority claimed from PCT/EP2012/060524 external-priority patent/WO2012168199A1/en
Publication of MX2013013911A publication Critical patent/MX2013013911A/en
Publication of MX355467B publication Critical patent/MX355467B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The present invention concerns human antibodies recognising the human C5a receptor. By binding to C5aR the antibodies inhibit C5a signalling, whereby the pro- inflammatory signal is inhibited. Based on the role of C5a and its receptor in stimulation of inflammation the invention further relates to therapeutic use of said human anti-C5aR antibodies and in particular in relation to treatment of immunological disorders.
MX2013013911A 2011-06-06 2012-06-04 Therapeutic antibodies. MX355467B (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP11168787 2011-06-06
US201161505137P 2011-07-07 2011-07-07
EP12159172 2012-03-13
PCT/EP2012/060524 WO2012168199A1 (en) 2011-06-06 2012-06-04 Therapeutic antibodies

Publications (2)

Publication Number Publication Date
MX2013013911A MX2013013911A (en) 2014-01-24
MX355467B true MX355467B (en) 2018-04-19

Family

ID=44315181

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013013911A MX355467B (en) 2011-06-06 2012-06-04 Therapeutic antibodies.

Country Status (1)

Country Link
MX (1) MX355467B (en)

Also Published As

Publication number Publication date
MX2013013911A (en) 2014-01-24

Similar Documents

Publication Publication Date Title
MX2015007751A (en) Anti-gdf15 antibodies.
BR112013031198A8 (en) therapeutic antibodies
PH12015500114B1 (en) HUMAN ANTIBODIES TO GFRa3 AND METHODS OF USE THEREOF
MX2011012691A (en) Combination of a tnf-alpha antagonist and a vegf antagonist for use in the treatment or prevention of diseases of the eye.
WO2014145159A3 (en) Charge-engineered antibodies or compositions of penetration-enhanced targeting proteins and methods of use
MX2018009524A (en) Arginine - free tnfr : fc- fusion polypeptide compositions and methods of use.
UA107827C2 (en) Antibody cd40
TN2012000414A1 (en) Forms of rifaximin and uses thereof
JO3199B1 (en) Substituted 5-fluoro-1H-pyrazolopyridines and their use
WO2011143318A3 (en) Anti-fgfr2 antibodies
UA104663C2 (en) Antibody binding to cd127
IN2014DN07149A (en)
MX340953B (en) Anti-gitr antibodies.
EA201390506A1 (en) POLYPEPTIDES THAT BIND THE COMPONENT C5 OF THE HUMAN COMPLEX
WO2012006421A3 (en) Diagnosis and treatment of breast cancer
WO2012006341A3 (en) Anti-ron antibodies
MY165499A (en) Monoclonal antibodies against tissue factor pathway inhibitor (tfpi)
GB201109238D0 (en) Antibodies
MX2023014921A (en) Anti-cd154 antibody having improved binding, functional and safety characteristics and use in human immunotherapy.
MX2014001766A (en) Neuregulin antibodies and uses thereof.
WO2014028668A3 (en) Stem cell enhancing therapeutics
MX2013011421A (en) Pyrazolo pyrimidine derivatives.
MX356745B (en) A human monoclonal antibody against the vp1 protein of jc virus.
MX2015012580A (en) The use of sdf-1 to mitigate scar formation.
EA201390314A1 (en) SUPERNATANT, CONDITIONED BY ACTIVATED LEUKOCITES, AND ITS USE FOR THE HEALING OF THE RAS

Legal Events

Date Code Title Description
FG Grant or registration